

5663 8159 5017 8353 5843 8164 Inventory (LIFO) Other 1059 799 1565 15814 16902 **Current Assets** 16542 12029 3061 11080 Accts Payable Debt Due 11255 11136 1059 10269 9613 22054 22583 26170

ANNUAL RATES Past Est'd '20-'22 Past 10 Yrs. to '26-'28 of change (per sh) 5 Yrs. Sales "Cash Flow" 7.5% 7.0% 8.0% 3.0% 3.0% 2.0% Earnings Dividends Book Value 7.0% 9.0% 4.5% 1.0% 2.0% 9.5% 1.5% 5.5%

Other

Current Liab.

Fiscal Year	QUARTERLY SALES (\$ mill.) A Nov.30 Feb.28 May 31 Aug.31				Full Fiscal
Ends	NOV.30	Feb.28	May 31	Aug.31	Year
2020	34340	35820	34631	34746	139537
2021	31438	32779	34030	34262	132509
2022	33901	33756	32597	32449	132703
2023	33382	34862	35415	34341	138000
2024	35200	36250	36500	36050	144000
Fiscal	EARNINGS PER SHARE ABFull				
Year Ends	Nov.30	Feb.28	May 31	Aug.31	Fiscal Year
2020	1.37	1.52	.83	1.02	4.74
2021	1.09	1.26	1.38	1.17	4.91
2022	1.68	1.59	.96	.80	5.04
2023	1.16	1.16	1.00	.68	4.00
2024	1.20	1.25	1.18	1.12	4.75
Cal-	QUARTERLY DIVIDENDS PAID C =				Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2019	.44	.44	.4575	.4575	1.80
2020	.4575	.4575	.4675	.4675	1.84
2021	.4675	.4675	.4775	.4775	1.89
2022	.4775	.4775	.48	.48	1.92
2023	.48	.48			

drug distributor, anchored by its network of drugstores in North America and Europe. As of 8/31/22, it operated 13,343 stores across the globe, including 8,889 locations in 50 states, Puerto Rico, and the U.S. Virgin Islands. In 2022, pharmacy contributed 74% of sales; Other general merchandise, 26%. Stores average

Walgreens Boots Alliance's fiscal 2023 (ends August 31st) has proven to be a **disappointment.** Its 8.7% May-quarter revenue rise beat consensus estimates by \$1.3 billion, but share earnings grew only by 4.2% to \$1.00, missing consensus by \$0.07. While this was the first positive earnings comparison since fiscal 2022's February period, it was not indicative of improved performance. In fact, management cut its 2023 earnings outlook to \$4.00-\$4.05, from \$4.45-\$4.65, suggesting yet another quarter of lower earnings. Operating margins have been under pressure from declining COVID-related demand, a weaker respiratory season leading to fewer front-store visits, and lower CityMD urgent care traffic. Other causes include higher labor costs and the cost of integrating recent acquisitions. Net income was also hurt by the absence of equity earnings from AmerisourceBergen (ABC) following the loss of Walgreens' majority holding and by a higher tax rate.

We look for some improved performance in fiscal 2024. Management expects low- to mid-single-digit operating income growth despite lower sale and leaseback

ees. Acquired 2,186 Rite Aid stores in September, 2017. Off. & dir. own 17.5% of stock; Vanguard, 6.9%; BlackRock, Inc., 6.4% (12/22 Proxy). Pres.:John Standley. CEO: Rosalind Brewer. Chairman: Stefano Pessina. Inc.: IL. Addr.: 108 Wilmot Road, Deerfield, IL 60015. Tel.: 847-914-2500. Internet: www.walgreens.com.

activity and lower COVID-19 contribution. It will also grow faster than net income, given the recent sale of much of its ABC holdings, a higher tax rate, and an expected negative impact from its non-controlling interest. Walgreens plans to raise its operating income by expanding its cost-management program to yield an additional \$800 million in annual savings by 2024 yearend. Leadership also plans to reduce capital and project spend, and optimize working capital. Meantime, it paid down debt with proceeds from selling its shares in ABC and its remaining shares in Option Care Health. Separately, while U.S. Healthcare revenues nearly quadrupled in fiscal 2023's first nine months on acquisitions and strong internal growth, the segment remains unprofitable. Management has initatives to control its costs and to realize increased synergies between the unit and the core drugstore business.

Walgreens shares are untimely. However, income-oriented investors may appreciate their generous dividend yield, and long-term holders, an attractive 3- to 5year total return potential. Phillip M. Seligman

July 21, 2023

(A) Fiscal year ends August 31st. (B) Based on diluted shares. Excludes nonrecurring gains/(losses): '10, (4¢); '11, 30¢; '12, (11¢); '13, (5¢); '14, (90¢); '15, 12¢; '16, (77¢); '17,

(\$1.32); '18, (67¢); '19, (\$1.68); '20, (\$4.22); '21, (\$1.98); '22, (\$0.03); '23 9 mos., (\$0.86). May not add due to rounding. Next earnings report due mid-October.

(C) Dividends historically paid in March, June, Sept., and Dec. ■ Direct stock purchase plan avail. (includes dividend reinvest.). (D) In millions.

Company's Financial Strength Stock's Price Stability A 75 Price Growth Persistence **Earnings Predictability** 80